The use of CSII therapy in individuals with insulin-resistant T2D is both safe and effective for improving glucose control and reducing insulin usage, although without a sustainable reduction in BM, BP, or lipid profile. The gene discussed is INS; the disease is type 2 diabetes mellitus.